ResMed (RMD) Reports In-Line Q3 EPS

ResMed (NYSE: RMD) reported Q3 EPS of $0.65, in-line with the analyst estimate of $0.65. Revenue for the quarter came in at $422.5 million versus the consensus estimate of $425.76 million.

For earnings history and earnings-related data on ResMed (RMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79